CRISPR Therapeutics (CRSP) highlights strategic priorities and anticipated 2026 milestones; -Starting 2026 with a strong balance sheet with approximately USD 2bln in cash, cash equivalents, and marketable securities
Importance
Level 1
- Continued global commercialization and adoption of CASGEVY, with ongoing quarterly updates.
- Global regulatory submissions for CASGEVY in patients ages 5 – 11 are expected to be initiated by Vertex in the first half of 2026.
- Updates from CTX310® are expected in the second half of 2026.
- Updates from the Lp(a) program are expected in 2026.
- Top-line Phase 2 clinical data from CTX611 in patients undergoing total knee arthroplasty (TKA) are expected in the second half of 2026.
- Updates across autoimmune disease and immuno-oncology for zugocabtagene geleucel (zugo-cel; formerly CTX112™) are expected in the second half of 2026.
- The Company expects to initiate a clinical trial for CTX460 in alpha-1 antitrypsin deficiency (AATD) in mid-2026.
- The Company expects to initiate a clinical trial for CTX340 in refractory hypertension in the first half of 2026.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#METALS#EU SESSION#US SESSION#METALS & MINING#DXY#US EQUITIES